Sugi Predict

Sugi Predict / Compounds / SCHEMBL3279475

SCHEMBL3279475

SCHEMBL3279475

CC(=O)N1CCN(c2ccc(Nc3nc(Nc4ccc5c(C)n[nH]c5c4)c4cc[nH]c4n3)cc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 5/20 0.51
▸ JAK2 O60674 1/20 0.51
▸ BRD4 O60885 1/20 0.51
▸ ALK Q9UM73 1/20 0.49
▸ JAK3 P52333 5/20 0.49
▸ BTK Q06187 4/20 0.49
▸ EGFR P00533 3/20 0.48
▸ PTK2 Q05397 2/20 0.47
▸ FLT3 P36888 2/20 0.47
▸ CDK1 P06493 2/20 0.45
▸ CCNB1 P14635 1/20 0.45
▸ AURKA O14965 1/20 0.44
▸ CDK4 P11802 1/20 0.44
▸ CDK2 P24941 1/20 0.44
▸ CDK7 P50613 1/20 0.44
▸ CDK9 P50750 1/20 0.44
▸ AURKB Q96GD4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3283451 0.87 PTK2 (0.57) JAK2BRD4JAK3BTKEGFR
SCHEMBL3286821 0.86 SYK (0.69) SYKJAK2BRD4ALKJAK3
SCHEMBL3281334 0.84 EGFR (0.61) SYKJAK2BRD4ALKJAK3
SCHEMBL12085284 0.82 SYK (0.60) SYKJAK2BRD4ALKJAK3
SCHEMBL1015533 0.81 SYK (0.57) SYKJAK2BRD4ALKJAK3
SCHEMBL3279212 0.80 BRD4 (0.53) SYKJAK2BRD4ALKJAK3
SCHEMBL3279674 0.80 FLT3 (0.48) SYKJAK2BRD4ALKEGFR
SCHEMBL12085413 0.80 JAK3 (0.66) SYKALKJAK3BTKEGFR
SCHEMBL1018509 0.79 BRD4 (0.60) SYKJAK2BRD4ALKJAK3
SCHEMBL12085396 0.79 JAK3 (0.53) SYKALKJAK3BTKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 — — US claimed
WO-2009026107-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 — — WO claimed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 — — US claimed
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 — — US disclosed
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 — — US disclosed
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 — — US disclosed
WO-2009026107-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 — — WO disclosed
WO-2009026107-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 — — WO disclosed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 — — US disclosed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 — — US disclosed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054425-A1 PROTEIN KINASE INHIBITORS SYK, JAK2, BTK SYK 1/4885JAK2 2/4885BRD4 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.